BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 17447891)

  • 1. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.
    Parisiadou L; Xie C; Cho HJ; Lin X; Gu XL; Long CX; Lobbestael E; Baekelandt V; Taymans JM; Sun L; Cai H
    J Neurosci; 2009 Nov; 29(44):13971-80. PubMed ID: 19890007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
    Pedro L; PadrĂ³s J; Beaudet L; Schubert HD; Gillardon F; Dahan S
    Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the autophosphorylation sites of LRRK2.
    Kamikawaji S; Ito G; Iwatsubo T
    Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
    Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
    J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
    Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
    J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
    Kalogeropulou AF; Purlyte E; Tonelli F; Lange SM; Wightman M; Prescott AR; Padmanabhan S; Sammler E; Alessi DR
    Biochem J; 2022 Sep; 479(17):1759-1783. PubMed ID: 35950872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
    Rudenko IN; Cookson MR
    Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.
    Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP
    Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assaying the kinase activity of LRRK2 in vitro.
    Lewis PA
    J Vis Exp; 2012 Jan; (59):. PubMed ID: 22301813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
    Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
    Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.